Cargando…

Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial

Hyperimmune plasma from patients convalescing from COVID-19 is a potential treatment for severe COVID-19 in other patients. We conducted a multicenter, one-arm, proof-of-concept interventional study. Patients with COVID-19 with moderate-to-severe acute respiratory distress syndrome, elevated C-react...

Descripción completa

Detalles Bibliográficos
Autores principales: Perotti, Cesare, Baldanti, Fausto, Bruno, Raffaele, Del Fante, Claudia, Seminari, Elena, Casari, Salvatore, Percivalle, Elena, Glingani, Claudia, Musella, Valeria, Belliato, Mirko, Garuti, Martina, Meloni, Federica, Frigato, Marilena, Di Sabatino, Antonio, Klersy, Catherine, De Donno, Giuseppe, Franchini, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716363/
https://www.ncbi.nlm.nih.gov/pubmed/33256382
http://dx.doi.org/10.3324/haematol.2020.261784
_version_ 1783619144162213888
author Perotti, Cesare
Baldanti, Fausto
Bruno, Raffaele
Del Fante, Claudia
Seminari, Elena
Casari, Salvatore
Percivalle, Elena
Glingani, Claudia
Musella, Valeria
Belliato, Mirko
Garuti, Martina
Meloni, Federica
Frigato, Marilena
Di Sabatino, Antonio
Klersy, Catherine
De Donno, Giuseppe
Franchini, Massimo
author_facet Perotti, Cesare
Baldanti, Fausto
Bruno, Raffaele
Del Fante, Claudia
Seminari, Elena
Casari, Salvatore
Percivalle, Elena
Glingani, Claudia
Musella, Valeria
Belliato, Mirko
Garuti, Martina
Meloni, Federica
Frigato, Marilena
Di Sabatino, Antonio
Klersy, Catherine
De Donno, Giuseppe
Franchini, Massimo
author_sort Perotti, Cesare
collection PubMed
description Hyperimmune plasma from patients convalescing from COVID-19 is a potential treatment for severe COVID-19 in other patients. We conducted a multicenter, one-arm, proof-of-concept interventional study. Patients with COVID-19 with moderate-to-severe acute respiratory distress syndrome, elevated C-reactive protein level and need for mechanical ventilation and/or continuous positive airway pressure were enrolled. One to three units (each of 250-300 mL) of hyperimmune plasma (neutralizing antibody titer ≥1:160) were administered. The primary outcome measure was 7-day hospital mortality. Secondary study outcomes were PaO2/FiO2, changes in laboratory and radiological parameters, weaning from mechanical ventilation and safety of the intervention. The study enrolled 46 patients between March 25 and April 21, 2020. The mean age of the patients was 63 years and 61% were male. Thirty of the patients were on continuous positive airway pressure and seven were intubated. The mean PaO2/FiO2 was 128 (standard deviation [SD] 47). Bilateral infiltrates on chest X-ray were present in 36 patients (84%). The mean duration of symptoms and ARDS was 14 (SD 7) and 6 (SD 3) days, respectively. Three patients (6.5%) died within 7 days as compared to an expected 15% according to national statistics and 30% in a small concurrent cohort of 23 patients. The upper one-sided 90% confidence interval (CI) was 13.9%, allowing rejection of the null hypothesis of a 15% mortality. The PaO2/FiO2 increased by 112 units (95% CI: 82-142) in survivors and the severity of the chest X-ray findings decreased in 23% (95% CI: 5%-42%). C-reactive protein, ferritin and lactate dehydrogenase levels decreased by 60%, 36% and 20%, respectively. Weaning from continuous positive airway pressure was achieved in 26/30 patients and it was possible to extubate three of the seven patients who had been intubated. Five serious adverse events occurred in four patients (2 likely and 2 possibly treatment-related). In conclusion, hyperimmune plasma showed promising benefits in COVID-19. Although these benefits need to be confirmed in a randomized controlled trial, this proof-of-concept study could open the way to future developments including hyperimmune plasma banking, standardized pharmaceutical products and monoclonal antibodies.
format Online
Article
Text
id pubmed-7716363
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-77163632020-12-10 Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial Perotti, Cesare Baldanti, Fausto Bruno, Raffaele Del Fante, Claudia Seminari, Elena Casari, Salvatore Percivalle, Elena Glingani, Claudia Musella, Valeria Belliato, Mirko Garuti, Martina Meloni, Federica Frigato, Marilena Di Sabatino, Antonio Klersy, Catherine De Donno, Giuseppe Franchini, Massimo Haematologica Article Hyperimmune plasma from patients convalescing from COVID-19 is a potential treatment for severe COVID-19 in other patients. We conducted a multicenter, one-arm, proof-of-concept interventional study. Patients with COVID-19 with moderate-to-severe acute respiratory distress syndrome, elevated C-reactive protein level and need for mechanical ventilation and/or continuous positive airway pressure were enrolled. One to three units (each of 250-300 mL) of hyperimmune plasma (neutralizing antibody titer ≥1:160) were administered. The primary outcome measure was 7-day hospital mortality. Secondary study outcomes were PaO2/FiO2, changes in laboratory and radiological parameters, weaning from mechanical ventilation and safety of the intervention. The study enrolled 46 patients between March 25 and April 21, 2020. The mean age of the patients was 63 years and 61% were male. Thirty of the patients were on continuous positive airway pressure and seven were intubated. The mean PaO2/FiO2 was 128 (standard deviation [SD] 47). Bilateral infiltrates on chest X-ray were present in 36 patients (84%). The mean duration of symptoms and ARDS was 14 (SD 7) and 6 (SD 3) days, respectively. Three patients (6.5%) died within 7 days as compared to an expected 15% according to national statistics and 30% in a small concurrent cohort of 23 patients. The upper one-sided 90% confidence interval (CI) was 13.9%, allowing rejection of the null hypothesis of a 15% mortality. The PaO2/FiO2 increased by 112 units (95% CI: 82-142) in survivors and the severity of the chest X-ray findings decreased in 23% (95% CI: 5%-42%). C-reactive protein, ferritin and lactate dehydrogenase levels decreased by 60%, 36% and 20%, respectively. Weaning from continuous positive airway pressure was achieved in 26/30 patients and it was possible to extubate three of the seven patients who had been intubated. Five serious adverse events occurred in four patients (2 likely and 2 possibly treatment-related). In conclusion, hyperimmune plasma showed promising benefits in COVID-19. Although these benefits need to be confirmed in a randomized controlled trial, this proof-of-concept study could open the way to future developments including hyperimmune plasma banking, standardized pharmaceutical products and monoclonal antibodies. Fondazione Ferrata Storti 2020-07-23 /pmc/articles/PMC7716363/ /pubmed/33256382 http://dx.doi.org/10.3324/haematol.2020.261784 Text en Copyright© 2020 Ferrata Storti Foundation http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Perotti, Cesare
Baldanti, Fausto
Bruno, Raffaele
Del Fante, Claudia
Seminari, Elena
Casari, Salvatore
Percivalle, Elena
Glingani, Claudia
Musella, Valeria
Belliato, Mirko
Garuti, Martina
Meloni, Federica
Frigato, Marilena
Di Sabatino, Antonio
Klersy, Catherine
De Donno, Giuseppe
Franchini, Massimo
Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial
title Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial
title_full Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial
title_fullStr Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial
title_full_unstemmed Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial
title_short Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial
title_sort mortality reduction in 46 patients with severe covid-19 treated with hyperimmune plasma. a proof-of-concept, single-arm, multicenter trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716363/
https://www.ncbi.nlm.nih.gov/pubmed/33256382
http://dx.doi.org/10.3324/haematol.2020.261784
work_keys_str_mv AT perotticesare mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT baldantifausto mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT brunoraffaele mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT delfanteclaudia mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT seminarielena mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT casarisalvatore mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT percivalleelena mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT glinganiclaudia mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT musellavaleria mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT belliatomirko mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT garutimartina mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT melonifederica mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT frigatomarilena mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT disabatinoantonio mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT klersycatherine mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT dedonnogiuseppe mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial
AT franchinimassimo mortalityreductionin46patientswithseverecovid19treatedwithhyperimmuneplasmaaproofofconceptsinglearmmulticentertrial